Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Fungal Infections
Caspofungin's mode of action and therapeutic applications evaluated
March 24th, 2006
Caspofungin's (CAS's) mode of action and therapeutic applications were evaluated. According to a study from France, "Since the last two decades, the incidence of invasive fungal infections has drastically increased. It becomes urgent to enlarge the panel of antifungal drugs with more potent activity and less toxicity." A. Datry and colleagues from CHU Pitie Salpetriere wrote, "Since the target of all previously available antifungal agents is the synthesis of ergosterol located in the fungal membrane, the fungicidal activity of echinocandins is based on the inhibition of the glucan synthesis. Caspofungin (CAS) (Cancidas MSD France), a cyclic...
Source: Drug Week (2006-03-24)
|
